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Background: The neurotrophic factor, S100B, is released primarily from astrocytes, with serum and CSF levels of
S100B reported as altered in schizophrenia. However, many of these reports are contradictory. Here, serum levels of
S100B in schizophrenia and influence of age, gender, medication and illness severity were examined.
Methods: Serum S100B levels were measured in patients with schizophrenia treated with clozapine. Lifestyle,
metabolic and illness severity parameters were correlated with S100B concentrations.
Results: Data showed raised serum levels of S100B in schizophrenia female patients, but not male patients,
compared to controls. Correlation analysis demonstrated a positive association between S100B serum
concentrations and BMI.
Conclusions: This study supports previous findings that adipocytes may contribute to S100B serum concentrations
in females, in addition to astrocytes. This study also supports the hypothesis that metabolic effects of medication,
lifestyle choices and the illness itself, may be contributing factors to altered levels of S100B.
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S100B is a calcium-binding protein of 92 residues, with
its gene located on 21q22.3 [1-3]. Within the central ner-
vous system (CNS), S100B is thought to be a marker for
astroglial activation, linking astrocyte dysfunction to
schizophrenia [1-4]. In addition to astrocytes, S100B is
released from many cell types, such as, adipocytes,
chondrocytes, cardiomyocytes and lymphocytes [5-13].
S100B can act in a paracrine and autocrine manner, where
low concentrations regulate proliferation and differenti-
ation of neurons and glia. S100B also acts as a neuro-
trophic factor, regulating dopaminergic and glutamatergic
synaptic function, in addition to synaptogenesis [1,2]. In
contrast, excessive levels of S100B promote the expression
of inducible nitric oxide synthase or pro-inflammatory cy-
tokines causing neuronal dysfunction and apoptosis. In
S100B knockout mice, increased brain-derived neuro-
trophic factor and decreased noradrenaline further suggest
a role for S100B in regulating the levels of neurotrophic* Correspondence: devk@tcd.ie
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reproduction in any medium, provided the orfactors and neurotransmitters [4]. Studies have also shown
that copy number variations in S100B as well as polymor-
phisms in its gene and promoter region are associated
with altered S100B protein levels in schizophrenia [14-21].
In addition, polymorphisms in the receptor for S100B,
RAGE (receptor for advanced glycation end products)
have been linked with schizophrenia, as have increased
levels of the soluble version of RAGE [22,23].
At the protein level, findings suggest that S100B is in-
creased in schizophrenia, and that these protein levels
are correlated with medication, gender, age and illness
severity [16,23-44]. Importantly, astrocytes express dopa-
mine receptors (DA2Rs) and antipsychotic medications
regulate the cellular release of S100B [45-48]. Of inter-
est, S100B is also expressed in immune cells (including
T cells and natural killer cells) and in adipocytes
suggesting it may have a role in altered immune re-
sponse and metabolic activity in schizophrenia [2,5-13].
Indeed, findings have suggested that altered S100B levels
in schizophrenia may be due to metabolic disorder, vis-
ceral obesity, diabetes and/or immune dysfunction in
this illness [6,8,9,34,49,50]. Here, the serum levels of
S100B in patients diagnosed with schizophrenia wasral Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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ness severity, type of medication, treatment time and
various metabolic factors, was examined. In this study,
focus was given toward patients treated with clozapine,
which has been previously shown to increase the inci-
dence of hyperglycaemia, diabetes and metabolic syn-
drome [51]. Moreover, stratification of patients and
control groups into male and female subpopulations
were performed to investigate the impact of body mass
index (BMI) on levels of S100B.
Methods
Study population
Ethical approval for this study was obtained from the St.
Vincent’s Hospital Fairview Ethics Committee, Dublin,
Ireland. Patients attending an urban mental health clinic
who met the DSM-IV-TR (Diagnostic and Statistical Man-
ual of Mental Disorders, 4th edition, Revised) [52] diag-
nostic criteria for schizophrenia were recruited. These
patients were treated with clozapine (n = 97) or depot
antipsychotic medication (n = 34). Healthy controls were
recruited from the same urban area with matched demo-
graphics (n = 27). Informed, written consent was gained
from all participants. Exclusion criteria for both groups in-
cluded (i) other psychiatric and neurological diagnoses, (ii)
a co-morbid diagnosis of substance abuse disorder and
(iii) those with an IQ < 70. Healthy controls recruited did
not have a significant physical disability or disease, or a
personal or family history of psychiatric illness. While psy-
chometric testing was not performed for individual partic-
ipants, all participating subjects were educated to at least
secondary school level in Ireland or equivalent. The age
range of the healthy controls was 25–57 years of age (with
mean age +/− standard deviation as 42.1 +/− 10.3) and
for patients treated with clozapine medication was
22–78 years of age (with mean age +/− standard deviation
as 42.5 +/− 12.2). Please see Table 1.
Treatment conditions
The range of treatment duration for patients treated
with clozapine was 0.25-19 years (with mean treatmentTable 1 Demographic data
Demographic data Patient group Control group
Subjects (Male:Famale) 97 (68:29) 27 (10:17)
Age (Range) (yrs) 42.5 ± 12.2 (22–78) 42.4 ± 10.3 (25–57)
Treatment duration (Range) (Yrs) 6.99 ± 4.64 (0.25-19) n/a
Daily dose (Range) (mg/day) 432.1 ± 185.7 (125–900) n/a
BPRS (18–126) 31 ± 9 n/a
SAN (0–125) 34 ± 18 n/a
Demographics of patients treated with clozapine and healthy control subjects.
Brief Psychiatric Rating Scale (BPRS), Scale for the Assessment of Negative
Symptoms (SANS). All values reported as mean +/− standard deviation. The
range of values is shown in brackets, were indicated.duration +/− standard deviation as 6.99 +/− 4.64 years). The
range of daily dose for clozapine medication was 125–
900 mg per day (with mean daily dose +/− standard devi-
ation as 432.1 +/− 185.7 mg per day). For depot medications
(I.M.) the range of daily dose and the mean daily dose +/−
standard deviation for (i) zuclopentixol was 50–450 per
week and 133.3 +/− 119.9 mg per week, n =9; (ii)
flupenthixol decanoate was 12.5-100 mg per week and
42.3 +/− 32.9 mg per week, n = 10; (iii) risperidone was
12.5-25 mg per week and 21.5 +/− 5.5 per week, n = 10; (iv)
flupehazine decanoate was 25–50 mg per week and
41.7 +/− 14.4 per week, n = 3; and (v) haloperidol was 25–
62.5 mg per week and 43.8 +/− 26.5 per week, n = 2. The
chlorpromazine equivalent doses expressed as mean mg per
day were as follows: clozapine 864 mg per day, zuclopentixol
133 mg per day, flupenthixol decanoate 423 mg per day, ris-
peridone 172 mg per day, flupehazine decanoate 833 mg per
day, and haloperidol 292 mg per day [53].
Illness severity and clinical variables
To assess illness severity within the patient group, the
Brief Psychiatric Rating Scale (BPRS) [54] and Scale for
The Assessment of Negative Symptoms (SANS) [55] was
administered by a trained clinical psychiatrist. The BPRS
assesses severity of psychopathology in patients with
schizophrenia, where values range between 18–126. The
SANS scale was used for assessing and rating the severity
of ‘negative symptoms’ in patients with schizophrenia,
where patients scored between 0–125. To determine sub-
ject demographic and metabolic syndrome risk profile,
clinical variables such as fasting cholesterol, HDL, LDL,
triglycerides, and fasting glucose were determined for all
participating subjects. Data including body mass index
(BMI), blood pressure (BP), smoking status, a known diag-
nosis of diabetes and hypertensive treatment was obtained
for all subjects. This enabled calculation of the Framing-
ham score for all individuals within the groups studied.
The Framingham score is a predictive score, showing the
percentage risk of a cardiovascular event occurring for
that participant in the subsequent 10 years [56].
S100B analysis
All participating subjects were fasting for at least 12 hours
prior to collection of blood sample for biochemical and
S100B analysis. Blood samples obtained for S100B analysis
were collected in monovette clotting activator serum tubes
(Sarstedt, UK) and centrifuged to separate serum fraction.
Serum samples were stored at −80°C until S100B analysis.
S100B analysis was conducted by commercial ELISA assay
(NKI-AVL, The Netherlands).
Statistical analysis
All statistical analysis was performed using Prism 5
GraphPad Software package. Unless otherwise stated,
Table 2 Biochemical data
Biochemical data Patient group Control group Significance
Fasting glucose 5.52 ± 0.09 5.06 ± 0.16 0.0167*
Triglycerides 2.33 ± 0.13 1.11 ± 0.12 0.0001***
HDL 1.07 ± 0.03 1.41 ± 0.11 0.0001***
LDL 3.03 ± 0.11 3.20 ± 0.18 0.4579
Total cholesterol 5.08 ± 0.13 5.11 ± 0.16 0.9117
Biochemical data of patients treated with clozapine (n = 97) and healthy
control subjects (n = 27). All biochemical values expressed as mMol/L.
Statistical analysis was performed using Student’s unpaired T test (two-tailed).
The significance levels (or alpha levels) were set at p < 0.05* and p < 0.001***.
Table 3 Cardiovascular disease risk factor and lifestyle data
CVD Risk factors Patient group Control group Significance
Smoking status (+) 58/95 (61%) 8/27 (30%) ~2 fold increase
Diabetes mellitus (+) 6/95 (6%) 1/27 (0.04%) >100 fold increase
Body Mass Index (BMI) 32.45 ± 0.62 27.53 ± 0.86 0.002***
Hypertension treatment 24/95 (25%) 6/27 (22%) no change
Systolic blood pressure 123 ± 1.5 122 ± 0.16 0.5675
Total cholesterol 5.08 ± 0.13 5.11 ± 0.16 0.9117
Framingham (%) 7.01 ± 0.62 5.31 ± 0.89 0.1797
Cardiovascular disease risk factors data and Framingham-10-year (%) risk of
cardiovascular disease incident of patients treated with clozapine (n = 97) and
healthy control subjects (n = 27). Data expressed as mean ± SEM. Statistical
analysis was performed using Student’s unpaired T test (two-tailed). The
significance levels (or alpha levels) were set at p < 0.001***.
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t-test (two-tailed) or one-way ANOVA (with Bonferroni
post-hoc test). Individual statistical tests are described in
figure legends. All data is shown as mean +/− SEM,
where n = number of subject samples. The significance
levels (or alpha levels) were set at p < 0.05*, p < 0.01**
and p < 0.001***.
Results
Demographic data of patient cohort studied
In order to determine changes in S100B levels in pa-
tients diagnosed with schizophrenia, the demographics
of control and patient cohorts were initially analysed. In
addition, the patient cohort was scored for both negative
and positive symptoms using the SANS and BPRS rating
scales, respectively. A total number of 97 subjects diag-
nosed with schizophrenia, treated with clozapine, and 27
healthy control subjects were recruited (Table 1). The
age range of the healthy controls was 25–57 years of age
(with mean age +/− standard deviation as 42.4 +/− 10.3)
and for patients treated with clozapine medication was
22–78 years of age (with mean age +/− standard devi-
ation as 42.5 +/− 12.2). No statistical difference was
found in age between these two groups (p = 0.962, Stu-
dent’s unpaired t-test, two-tailed). While the male:female
ratio was 57% for the patient group, this ratio was 41%
for the control group. The BPRS and SANS rating for
the patient group was 31 +/− 9 and 34 +/− 18, respect-
ively (Table 1). This data indicates a typical patient
population treated with clozapine displaying both posi-
tive and negative symptoms.
Metabolic parameters altered in clozapine treated patient
group
Cardiovascular disease is the leading cause of natural
death in patients with schizophrenia [57]. Furthermore, it
has been reported that patients diagnosed with schizo-
phrenia have abnormal metabolic parameters prior to
treatment with psychotropic medications [58]. In addition,
previous studies show that clozapine increases the inci-
dence of hyperglycaemia, diabetes and metabolic syn-
drome [51]. Here, a number of cardiovascular risk factors
were investigated for both patient and control groups. The
fasting glucose levels found in the patient group (5.52 +/−
0.09 mMol/L) compared to control group (5.06 +/− 0.16
mMol/L) was significantly raised (p = 0.0167, Student’s
unpaired t-test, two-tailed) (Table 2). Furthermore, statisti-
cally significant abnormalities in Triglyceride (2.33 +/−
0.13 mMol/L vs. 1.11 +/− 0.12 mMol/L) (p = 0.0001, Stu-
dent’s unpaired t-test, two-tailed) and HDL (1.07 +/− 0.03
vs. 1.41 +/− 0.11 mMol/L) (p = 0.0001, Student’s unpaired
t-test, two-tailed) levels were observed between patient
and control groups (Table 2). Notably, the levels of LDL
(3.03 +/− 0.11 vs. 3.20 +/− 0.18 mMol/L) (p = 0.4579,Student’s unpaired t-test, two-tailed) and total cholesterol
(5.08 +/− 0.13 vs. 5.11 +/− 0.16 mMol/L) (p = 0.9117, Stu-
dent’s unpaired t-test, two-tailed) were not different
between patient and control groups. These abnormal tri-
glyceride and HDL levels likely predispose the patient
group to an increased risk of cardiovascular and cerebro-
vascular disease. In addition, this data is in keeping with
previous observations that clozapine may alter metabolic
parameters [51].
Clozapine treated patient cohort display increased BMI
Given the observations that metabolic parameters were al-
tered in the patient cohort (Table 2) and that previous evi-
dence has linked clozapine to weight gain [59], further
analysis on cardiovascular risk was determined. In the
current study, the Framingham Score, a prediction of a
cardiovascular event occurring over the next 10 years, was
calculated in the patient population analysed. No signifi-
cant difference in the Framingham Score between patients
and controls (7.01 +/− 0.62% vs. 5.31 +/− 0.89%) (p =
0.1797, Student’s unpaired t-test, two-tailed) was observed.
In addition, an approximate 2-fold increase was observed
in smoking rate between patient (61%) and control (30%)
groups (Table 3). This finding has been well documented
in patients with schizophrenia [60]. The data also showed
a greater than 100-fold increase in diagnosis of type 2 dia-
betes within the patient group (6%) compared to control
group (0.04%) was noted (Table 3). Importantly, a
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vs. 27.53 +/− 0.86) between patient and control groups
(p = 0.0002, Student’s unpaired t-test, two-tailed) was
observed (Table 3). This increase in BMI for the patient
group is in concordance with the previous known associ-
ation between patients treated with clozapine medication
and subsequent weight gain [59].
The serum levels of S100B in patients treated with
clozapine and healthy control subjects
A number of previous studies have suggested that the
levels of S100B protein are altered in patients with schizo-
phrenia, with the general observation that S100B levels are
increased [16,19,29,61-63]. While some controversy exists,
studies suggest that medication status may alter S100B
concentrations [25,31,41,43,44]. Here, a study to further
investigate the role of S100B in schizophrenia was
conducted comparing patients treated with clozapine and
healthy controls. The data showed no statistical significant
difference in S100B serum concentration between patients
treated with clozapine (79.48 +/− 4.04 ng/L, n = 97) and
control groups (67.78 +/− 4.01 ng/L, n = 27) (p = 0.1438,
Student’s unpaired t-test, two-tailed) (Figure 1). These re-
sults suggest that S100B serum concentration in patients
with schizophrenia, treated with clozapine, are not signifi-
cantly altered when compared to healthy controls, when
analysing the whole sample population.
S100B serum concentration is not related to age,
treatment time or illness severity
Previous reports have suggested a correlation between
the levels of S100B and age [39,61-63], antipsychotic(97) (27)
Figure 1 S100B concentration for patients treated with
clozapine and healthly control subjects. Data shows S100B
concentration for patients treated with clozapine (79.48 +/− 4.04 ng/L,
n = 97) and healthy control subjects (67.78 +/− 4.01 ng/L, n = 27). The
data showed no statistical significant difference in S100B serum
concentration between patients treated with clozapine and control
groups (p = 0.1438, Student’s unpaired t-test, two-tailed). All statistical
analysis was performed using Student’s unpaired T test (two-tailed).
Number of subjects in parenthesise (patients:controls).medication [31,33,34,41-44], illness severity and symp-
toms [40,43]. However, these reports have in best part
been conflicting. Thus, to further investigate these dis-
cordant findings, the age, treatment time and illness se-
verity of participating subjects was recorded and plotted
against S100B serum concentration. The data showed no
significant correlation between the levels of S100B and
age (Pearson’s correlation; r = −0.06026; p value (two
tailed) = 0.7653 for control, Pearson’s correlation; r =
0.09035; p value (two tailed) = 0.3763 for clozapine
treated patients) (Figure 2A), treatment time (Pearson’s
correlation; r = −0.02633; p value (two tailed) = 0.7980)
(Figure 2B), acute illness severity (BPRS) (Pearson’s cor-
relation; r = 0.04655; p value (two tailed) = 0.649)
(Figure 2C) or negative symptoms illness severity (SANS)
(Pearson’s correlation; r = 0.1874; p value (two tailed) =
0.8547) (Figure 2D), where the alpha value = 0.05.
Effects of medication on S100B serum concentration
While some studies have reported the levels of S100B to
be altered dependent on medication, these reports have
been contradictory [31,33,35,41-44]. Furthermore, little
is known about the direct effects of antipsychotic medi-
cation on glial cells within the central nervous system.
To determine whether choice of antipsychotic medica-
tion effects the levels of S100B, this study also compared
patients treated with clozapine (n = 97) and those trea-
ted with depot antipsychotic medications comprising
zuclopentixol (n =9), flupenthixol decanoate (n = 10), ris-
peridone (n = 10), flupehazine decanoate (n = 3) and
haloperidol (n = 2). The results showed no statistical sig-
nificant difference between clozapine treated patients
(79.48 +/− 4.04 ng/L, n = 97), depot antipsychotic
treated patients (73.08 +/− 6.64 ng/L, n = 34) and
healthy controls (67.78 +/− 4.01 ng/L, n = 27) (p =
0.2706, clozapine treated patients and antipsychotic
treated patients vs. control, one-way ANOVA and
Bonferroni post-hoc test) (Figure 3). Taken together
these data suggest that choice of antipsychotic medica-
tion has no significant effect on S100B serum concentra-
tion in patients with schizophrenia.
S100B levels are elevated in female patients with
schizophrenia
Given that previous studies have suggested that the levels
of S100B may be dependent on gender [62-64], in the
current study these levels were examined in male and fe-
male healthy control and patient groups. The data showed
a statistically significant increase in levels of S100B in fe-
male patient group (97.78 +/− 10.34 ng/L, n = 29) com-
pared to male patient group (73.24 +/− 3.70 ng/L, n = 68)
(p = 0.0101, one-way ANOVA and Bonferroni post-hoc
test) (Figure 4). Additionally, a statistically significant dif-
ference was found in S100B serum concentration between
A B
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Figure 2 S100B concentration in patients treated with clozapine. S100B concentration plotted against (A) age, (B) time on clozapine
treatment in years, (C) BPRS and (D) SANS. No notable correlations between S100B concentration any of these parameters in patient group were
observed: age (Pearson’s correlation; r = −0.06026; p value (two tailed) = 0.7653 for control, Pearson’s correlation; r = 0.09035; p value (two tailed) =
0.3763 for clozapine treated patients), treatment time (Pearson’s correlation; r = −0.02633; p value (two tailed) = 0.7980), acute illness severity
(BPRS) (Pearson’s correlation; r = 0.04655; p value (two tailed) = 0.649), negative symptoms illness severity (SANS) (Pearson’s correlation; r = 0.1874;





















Figure 3 Levels of S100B concentration in patients treated with
depot medications. Graph shows S100B concentration for patients
treated with clozapine and those treated with depot medication
compared to healthy control subjects. No statistical significance was
observed between the groups. Number of subjects in parenthesise.
Patients treated with depot medications include those treated with
zuclopentixol (n =9), flupenthixol (n = 10), risperidone (n = 10),
flupehazine (n = 3) and haloperidol (n = 2).
O’Connell et al. BMC Psychiatry 2013, 13:146 Page 5 of 9
http://www.biomedcentral.com/1471-244X/13/146female patients and female controls (68.24 +/− 4.72 ng/L,
n = 17) (p = 0.0101, one-way ANOVA and Bonferroni
post-hoc test) (Figure 4). In contrast, no statistical differ-
ence was observed between male patient group and male
control group (67.00 +/− 7.61 ng/L, n = 10) (as determined
by one-way ANOVA and Bonferroni post-hoc test)
(Figure 4). The data is supportive of previous studies indi-
cating the levels of S100B differ in male and female gen-
ders. Studies have suggested that adipocytes release S100B,
in addition to astrocytes. Furthermore reports show that
insulin reduces the levels of S100B in adipocytes and astro-
cytes [10]. Of interest, overweight, visceral obesity and in-
sulin resistance may be correlated with levels of S100B in
schizophrenia [9]. Therefore, in addition to S100B being a
marker for aberrant astrocyte function, it may also be asso-
ciated with altered adipocyte cellular function.
Levels of 100B correlate with BMI in female patients with
schizophrenia
To further examine if metabolic factors are associated
with increased serum levels of S100B in females, a cor-
relation between BMI and levels of S100B were exam-
ined in male and female patients. As indicated above,
the data showed a statistically significant difference in























Figure 4 S100B concentration in male and female patients
treated with clozapine and healthy control subjects. Data shows
significant statistical difference in S100B concentration between
male (73.24 +/− 3.70 ng/L, n = 68) and female (97.78 +/− 10.34 ng/L,
n = 29) patients treated with clozapine (p = 0.0101, one-way ANOVA
and Bonferroni post-hoc test). S100B concentration in female
patients showed significant statistical significance compared to
female controls (68.24 +/− 4.72 ng/L, n = 17) (p = 0.0101, one-way
ANOVA and Bonferroni post-hoc test). No statistical difference was
observed between male patient group and male control group
(67.00 +/− 7.61 ng/L, n = 10) (as determined by one-way ANOVA
and Bonferroni post-hoc test) (Figure 4). Data represented as mean
+/− SEM. Number of subjects in parenthesise.
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two-tailed) (Table 3). Further analysis showed that fe-
male patients (35.31 +/− 1.16, n = 29) displayed in-
creased BMI compared to male patients (31.37 +/− 0.69,
n = 68) and compared to female controls (27.38 +/−
1.01, n = 17) and male controls (27.24 +/− 1.69, n = 10)
(p = 0.0001, male patients and female controls vs. female
patients, one-way ANOVA and Bonferroni post-hoc test)
(Figure 5A). In addition, S100B serum concentration
plotted against BMI showed a statistically significant cor-
relation (Pearson’s correlation; r = 0.4868; p value (two
tailed) = 0.0117) in female patients with schizophrenia,
treated with clozapine (Figure 5C) but was not corre-
lated in the male patient group (Pearson’s correlation;
r = −0.2395; p value (two tailed) = 0.0511) (Figure 5B).
An increase in BMI in the female patient group com-
pared to male patient group and control groups is likely
associated increased adipose tissue and is in agreement
with the hypothesis that S100B protein in serum is
influenced by not only altered release from astrocytes
but also due to release from adipocytes in schizophrenia.
Discussion
In the current study 97 subjects diagnosed with schizo-
phrenia, treated with clozapine, 34 patients treated with
depot antipsychotic medications and 27 healthy controlsubjects were recruited. Fasting glucose levels, triglycer-
ide and HDL were raised in the patients compared to
healthy controls. As expected the patient group showed
an increased percentage of subjects who smoked and in-
creased numbers with a known diagnoses of type 2 dia-
betes compared to control. Patients diagnosed with
schizophrenia also showed higher BMI levels compared
to healthy controls. When comparing S100B levels, no
statistical difference was found between patients and
controls. The serum levels of S100B were also not corre-
lated with age, treatment time or illness severity. Ana-
lysis of S100B serum concentrations in patients treated
with the depot antipsychotic medications including
zuclopentixol, flupenthixol, risperidone, flupehazine and
haloperidol also showed no observable differences in
S100B levels compared to control. Importantly, the data
here showed that S100B levels were elevated in female
patients with schizophrenia compared to male patients
and to those female and male healthy control subjects.
Of interest, BMI levels were also elevated in female pa-
tients compared to male patients and healthy control
groups. A correlation analysis showed that levels of
S100B increased with BMI in female patients with
schizophrenia. Taken together, the data suggested that
levels of S100B are altered in schizophrenia and these
levels are also likely related to patients BMI, in addition
to astrocyte dysfunction.
The question has emerged if S100B is a specific
marker for astrocyte dysfunction in schizophrenia? The
widespread cellular expression of S100B and the lack of
disease specificity for this protein [34,49], has questioned
if S100B is a sole marker for astrocytes [50]. Astrocytes
have diverse roles including (i) direct communication of
astrocytic end-feet with endothelial cells that allows as-
trocytes to control the blood–brain-barrier; (ii) uptake of
neurotransmitters, such as glutamate at the synaptic
cleft, that allow astrocytes to regulate synaptic transmis-
sion and excitoxicity; and (iii) release of transmitters,
growth factors, and cytokine/chemokines, allowing as-
trocytes to regulate cellular communication, migration
and survival, for example of neurons and lymphocytes
[65]. It is significant that astrocytes also play a role in
scar formation after CNS injury, thus having apparent
opposing roles in physiology and pathophysiology. In
disease, astrocytes have been suggested to play roles in a
range of psychiatric, neurological and neurodegenerative
disorders. Previous studies have focused on the role of
S100B in astrocytes, and suggested that astrocyte dys-
function may increase release of S100B in schizophrenia.
However, S100B is also released from many other cell
types including adipocytes and a number of in vitro
studies have shown that levels of S100B from these fat
cells can be regulated by, for example, glucagon, adren-
aline and insulin [10,66,67]. Moreover, chronic fasting,













































Figure 5 S100B concentration in female patients treated with clozapine and healthy control subjects. (A) Data shows significant statistical
difference in BMI levels between male (31.37 +/− 0.69, n = 68) and female (35.31 +/− 1.16, n = 29) patients treated with clozapine. BMI levels in
female patients also showed significant statistical significance compared to female controls (27.38 +/− 1.01, n = 17) and male controls (27.24 +/− 1.69,
n = 10) (p = 0.0001, male patients and female controls vs. female patients, one-way ANOVA and Bonferroni post-hoc test). Data represented as
mean +/− SEM. Number of subjects in parenthesise. Correlation between S100B concentration and BMI for (B) male and (C) female patients
treated with clozapine. A significant correlation was observed for S100B concentration and BMI in female patients treated with clozapine
(Pearson r = 0.4868; p value (two tailed) = 0.0117). Number of subjects in parenthesise.
O’Connell et al. BMC Psychiatry 2013, 13:146 Page 7 of 9
http://www.biomedcentral.com/1471-244X/13/146weight gain and diet have also been shown to influence
serum levels of S100B in patients and animal models
[67,68]. The findings that S100B and BMI levels are ele-
vated in female patients compared to male patients and
to controls, and that S100B and BMI levels correlated in
female patients (but not male patients), are in line with
the hypothesis that visceral fat and altered adipocyte
function could be a mechanism explaining elevated
levels of S100B in schizophrenia [9,69]. On a more cau-
tionary note, these results equally suggest that S100B
can no longer be considered as a sole marker of astro-
cyte dysfunction in brain disease given its widespread
distribution.
Previous studies have suggested that S100B levels in
patients treated with clozapine are increased [33], which
in part is in agreement with the data in the current study
showing raised levels of S100B in female patients treated
with clozapine. The effects of clozapine are thought to
be mediated primarily via antagonism at 5HT2AR and
DA4R, with weak DA2R blocking activity [70]. Astro-
cytes express DA2Rs and activation of these receptors
using apomorphine decreases the levels of S100B in
these cells, via a signalling pathway that involves inhib-
ition of adenyl cyclase [46]. Moreover, antipsychotic
medications (such as clozapine, haloperidol and ris-
peridone), which block DA2Rs, also decrease S100B
levels [46,47]. Treatment of astrocytic C6 cells and
oligodendrocytic OLN-93 cells with haloperidol and clo-
zapine also decreases the levels of S100B [48]. This data
is in contrast with elevated levels of S100B observed in
patients diagnosed with schizophrenia [46]. However,contradictory to the hypothesis that astrocyte derived
S100B levels are raised in schizophrenia, is the finding
that chronic antipsychotic medication, such as haloperi-
dol or olanzapine, reduce astrocyte numbers in Macaque
Monkeys [71]. Recent data also demonstrated that insu-
lin downregulates levels of S100B in adipocytes (in
addition to astrocytes) suggesting that other cell types
may determine the levels of S100B [9]. Interestingly, mo-
lecular links between S100B, DA2Rs and schizophrenia
have been suggested where S100B has been shown to
interact with the third cytoplasmic loop of the DA2R,
and to enhance receptor signalling to ERK and inhibition
of adenylate cyclase [45,72-74]. In S100B transgenic ani-
mals, there is a decrease in the expression of DA2R
suggesting crosstalk between S100B and DA2R function
[75]. Taken together, these studies support the S100B/
DA2R protein complex as a molecular target for anti-
psychotic medications and possible aberrant S100B/
DA2R-mediated signalling in schizophrenia.
Conclusions
This current study showed that levels of S100B are
raised in female patients diagnosed with schizophrenia
and correlate with BMI, which is possibly linked to
higher levels of release from adipocytes. A limitation of
this study was the unequal distribution of genders
among the two groups (controls vs. patients). While
ANOVA tests were performed, these assumed the sam-
ple size were equal and thus may have been too liberal.
Another limitation of this study is the direct comparison
of S100B levels between patients on medication and
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have however reported that levels of S100B in drug naive
patients with schizophrenia are raised [32,42]. Notably,
however the levels of S100B were not correlated with
BMI in these reports. In this current study we also did
not investigate if the levels of S100B were associated
with genetic mutations reported in schizophrenia. While
it may be possible that our findings are explained, in
part, by pathogenetic mechanisms, further studies would
be required to determine this possibility, for example by
investigating the levels of S100B in siblings of patients
with schizophrenia. Moreover, further analysis of mole-
cules that are more specific to adipocytes (rather than
S100B) would be worthy of investigation. In addition,
cellular studies demonstrating the effects of anti-
psychotic medications on the release of S100B in adipo-
cytes would be warranted. In closing, while a number of
studies have demonstrated that levels of S100B are al-
tered in schizophrenia, many of these reports are contra-
dictory when suggesting that age, gender, medication
and illness severity all have an impact (or not) on S100B
levels. The study here suggested two important factors
that may help unify these apparent contradictory find-
ings. Firstly, that the serum S100B concentrations are
likely influenced by metabolic activity. Secondly, that the
levels of S100B are not solely dependent on astrocyte
dysfunction and may involve altered fat cell (adipocyte)
function. Thus, the data presented here supports previ-
ous studies that have suggested an association between
metabolic syndrome, diabetes and immune response
dysfunction in schizophrenia. The clinical implications
of this study are two-fold, firstly that S100B levels may
no longer be considered as a biomarker that is
dependent on neurological function alone, and secondly,
that regulating metabolic dysfunction in schizophrenia
may represent a novel drug target.
Competing interests
The authors declare that they have no competing interests.
Authors’ contributions
KKD and JT conceived the idea. KKD and KOC designed the methodology of
this study. KOC was the major contributor in subject recruitment, in clinical
and diagnostic assessments, in gathering experimental data and in
conducted all the statistical analyses. KKD and KOC were the major
contributors in the writing of the manuscript. All authors have approved the
final manuscript.
Acknowledgments
This work was supported by the Neuroscience Center, St. Vincent’s Hospital
Fairview, Dublin, Ireland and Molecular Neuropharmacology Research Group,
Trinity College Dublin, Dublin, Ireland.
Author details
1Molecular Neuropharmacology, Department of Physiology, School of
Medicine, Trinity College Institute of Neuroscience, Trinity College Dublin,
Dublin, Ireland. 2Department of Psychiatry, School of Medicine, Trinity
College Institute of Neuroscience, Trinity College Dublin, Dublin, IRELAND.
3Neuroscience Centre, St. Vincent’s Hospital Fairview, Fairview, Dublin,
Ireland.Received: 28 January 2013 Accepted: 6 May 2013
Published: 24 May 2013
References
1. Steiner J, Bogerts B, Schroeter ML, et al: S100B protein in
neurodegenerative disorders. Clin Chem Lab Med 2011, 49:409–24.
2. Rothermundt M, Ahn JN, Jörgens S: S100B in schizophrenia: an update.
Gen Physiol Biophys 2009, 28:F76–81.
3. Rothermundt M, Ponath G, Arolt V: S100B in schizophrenic psychosis. Int
Rev Neurobiol 2004, 59:445–70.
4. Schulte-Herbrüggen O, Hörtnagl H, Ponath G, et al: Distinct regulation of
brain-derived neurotrophic factor and noradrenaline in S100B knockout
mice. Neurosci Lett 2008, 442:100–3.
5. Muller N, Schwarz MJ: The immunological basis of glutamatergic
disturbance in schizophrenia: towards an integrated view. J Neural
Transm Suppl 2007, 72:269–80.
6. Beumer W, Drexhage RC, De Wit H, et al: Increased level of serum
cytokines, chemokines and adipokines in patients with schizophrenia is
associated with disease and metabolic syndrome.
Psychoneuroendocrinology 2012. In press.
7. Schwarz E, Guest PC, Rahmoune H, et al: Identification of a biological
signature for schizophrenia in serum. Mol Psychiatry 2012, 17:494–502.1.
8. Leonard BE, Schwarz M, Myint AM: The metabolic syndrome in
schizophrenia: is inflammation a contributing cause? J Psychopharmacol
2012, 26:33–41.
9. Steiner J, Myint AM, Schiltz K, et al: S100B Serum levels in schizophrenia
are presumably related to visceral obesity and insulin resistance.
Cardiovasc Psychiatry Neurol 2010, 2010:480707.
10. Steiner J, Walter M, Guest P, et al: Elevated S100B levels in schizophrenia
are associated with insulin resistance. Mol Psychiatry 2010, 15:3–4.
11. Streitbürger DP, Arelin K, Kratzsch J, et al: Validating serum S100B and
neuron-specific enolase as biomarkers for the human brain - a combined
serum, gene expression and MRI study. PLoS One 2012, 7:e43284.
12. Steiner J, Westphal S, Schroeter ML, et al: Increased S100B +NK cell counts in
acutely ill schizophrenia patients are correlated with the free cortisol index,
but not with S100B serum levels. Brain Behav Immun 2012, 26:564–7.
13. Muller N, Schwarz M: Schizophrenia as an inflammation-mediated
dysbalance of glutamatergic neurotransmission. Neurotox Res 2006,
10:131–48.
14. Zhai J, Cheng L, Dong J, et al: S100B gene polymorphisms predict
prefrontal spatial function in both schizophrenia patients and healthy
individuals. Schizophr Res 2012, 134:89–94.
15. Zhai J, Zhang Q, Cheng L, et al: Risk variants in the S100B gene,
associated with elevated S100B levels, are also associated with
visuospatial disability of schizophrenia. Behav Brain Res 2011, 217:363–8.
16. Dagdan E, Morris DW, Campbell M, et al: Functional assessment of a
promoter polymorphism in S100B, a putative risk variant for bipolar
disorder. Am J Med Genet B Neuropsychiatr Genet 2011, 156B:691–9.
17. Suchankova P, Baghaei F, Rosmond R, et al: Genetic variability within the
S100B gene influences the personality trait self-directedness.
Psychoneuroendocrinology 2011, 36:919–23.
18. Saus E, Brunet A, Armengol L, et al: Comprehensive copy number variant
(CNV) analysis of neuronal pathways genes in psychiatric disorders
identifies rare variants within patients. J Psychiatr Res 2010, 4:971–8.
19. Hohoff C, Ponath G, Freitag CM, et al: Risk variants in the S100B gene
predict elevated S100B serum concentrations in healthy individuals. Am
J Med Genet B Neuropsychiatr Genet 2010, 153B:291–7.
20. Roche S, Cassidy F, Zhao C, et al: Candidate gene analysis of 21q22:
support for S100B as a susceptibility gene for bipolar affective disorder
with psychosis. Am J Med Genet B Neuropsychiatr Genet 2007, 144B:1094–6.
21. Liu J, Shi Y, Tang J, et al: SNPs and haplotypes in the S100B gene reveal
association with schizophrenia. Biochem Biophys Res Commun 2005,
328:335–41.
22. Suchankova P, Klang J, Cavanna C, et al: Is the Gly82Ser polymorphism in
the RAGE gene relevant to schizophrenia and the personality trait
psychoticism? J Psychiatry Neurosci 2012, 37:122–8.
23. Steiner J, Walter M, Wunderlich MT, et al: A new pathophysiological aspect
of S100B in schizophrenia: potential regulation of S100B by its
scavenger soluble RAGE. Biol Psychiatry 2009, 65:1107–10.
24. Falcone T, Fazio V, Lee C, et al: Serum S100B: a potential biomarker for
suicidality in adolescents? PLoS One 2010, 5:e11089.
O’Connell et al. BMC Psychiatry 2013, 13:146 Page 9 of 9
http://www.biomedcentral.com/1471-244X/13/14625. Zhang XY, Xiu MH, da Chen C, et al: Increased S100B serum levels in
schizophrenic patients with tardive dyskinesia: association with
dyskinetic movements. J Psychiatr Res 2010, 44:429–33.
26. Steiner J, Bernstein HG, Bielau H, et al: S100B-immunopositive glia is
elevated in paranoid as compared to residual schizophrenia: a
morphometric study. J Psychiatr Res 2008, 42:868–76.
27. Ryoun Kim H, Kyung Lee M, Park DB: Increased serum S100B protein in
chronic schizophrenic patients in Korea. Clin Chem Lab Med 2007, 45:1561–3.
28. Rothermundt M, Ohrmann P, Abel S, et al: Glial cell activation in a
subgroup of patients with schizophrenia indicated by increased S100B
serum concentrations and elevated myo-inositol. Prog
Neuropsychopharmacol Biol Psychiatry 2007, 31:361–4.
29. Steiner J, Bielau H, Bernstein HG, et al: Increased cerebrospinal fluid and
serum levels of S100B in first-onset schizophrenia are not related to a
degenerative release of glial fibrillar acidic protein, myelin basic protein
and neurone-specific enolase from glia or neurones. J Neurol Neurosurg
Psychiatry 2006, 77:1284–7.
30. Rothermundt M, Falkai P, Ponath G, et al: Glial cell dysfunction in
schizophrenia indicated by increased S100B in the CSF. Mol Psychiatry
2004, 9:897–9.
31. Wiesmann M, Wandinger KP, Missler U, et al: Elevated plasma levels of S-100b
protein in schizophrenic patients. Biol Psychiatry 1999, 45:1508–1511.
32. Zhang XY, Xiu MH, Song C, et al: Increased serum S100B in never-
medicated and medicated schizophrenic patients. J Psychiatr Res 2010,
44:1236–40.
33. Qi LY, Xiu MH, da Chen C, et al: Increased serum S100B levels in chronic
schizophrenic patients on long-term clozapine or typical antipsychotics.
Neurosci Lett 2009, 462:113–7.
34. Schroeter ML, Steiner J: Elevated serum levels of the glial marker protein
S100B are not specific for schizophrenia or mood disorders. Mol
Psychiatry 2009, 14:235–7.
35. Schroeter ML, Abdul-Khaliq H, Krebs M, et al: Neuron-specific enolase is unaltered
whereas S100B is elevated in serum of patients with schizophrenia–original
research and meta-analysis. Psychiatry Res 2009, 167:66–72.
36. Pedersen A, Diedrich M, Kaestner F, et al: Memory impairment correlates
with increased S100B serum concentrations in patients with chronic
schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry 2008, 32:1789–92.
37. Ehrenreich H, Hinze-Selch D, Stawicki S, et al: Improvement of cognitive
functions in chronic schizophrenic patients by recombinant human
erythropoietin. Mol Psychiatry 2007, 12:206–20.
38. van Beveren NJ, van der Spelt JJ, de Haan L, et al: Schizophrenia-associated
neural growth factors in peripheral blood. A review. Eur Neuropsychopharmacol
2006, 16:469–80.
39. Schmitt A, Bertsch T, Henning U, et al: Increased serum S100B in elderly,
chronic schizophrenic patients: negative correlation with deficit
symptoms. Schizophr Res 2005, 80:305–13.
40. Rothermundt M, Ponath G, Glaser T, et al: S100B serum levels and long-
term improvement of negative symptoms in patients with
schizophrenia. Neuropsychopharmacology 2004, 29:1004–11.
41. Schroeter ML, Abdul-Khaliq H, Frühauf S, et al: Serum S100B is increased
during early treatment with antipsychotics and in deficit schizophrenia.
Schizophr Res 2003, 62:231–6.
42. Lara DR, Gama CS, Belmonte-de-Abreu P, et al: Increased serum S100B
protein in schizophrenia: a study in medication-free patients. J Psychiatr
Res 2001, 35:11–4.
43. Rothermundt M, Missler U, Arolt V, et al: Increased S100B blood levels in
unmedicated and treated schizophrenic patients are correlated with
negative symptomatology. Mol Psychiatry 2001, 6:445–9.
44. Gattaz WF, Lara DR, Elkis H, et al: Decreased S100-beta protein in
schizophrenia: preliminary evidence. Schizophr Res 2000, 43:91–95.
45. Liu Y, Buck DC, Neve KA: Novel interaction of the dopamine D2 receptor
and the Ca2+ binding protein S100B: role in D2 receptor function. Mol
Pharmacol 2008, 74:371–8.
46. Nardin P, Tramontina AC, Quincozes-Santos A, et al: In vitro S100B
secretion is reduced by apomorphine: effects of antipsychotics and
antioxidants. Prog Neuropsychopharmacol Biol Psychiatry 2011, 35:1291–6.
47. Herrmann AP, Lunardi P, Pilz LK, et al: Effects of the putative antipsychotic
alstonine on glutamate uptake in acute hippocampal slices. Neurochem
Int 2012. In press.
48. Steiner J, Schroeter ML, Schiltz K, et al: Haloperidol and clozapine decrease
S100B release from glial cells. Neuroscience 2010, 167:1025–31.49. Sen J, Belli A: S100B in neuropathologic states: the CRP of the brain?
J Neurosci Res 2007, 85:1373–80.
50. Steiner J, Bernstein HG, Bielau H, et al: Evidence for a wide extra-astrocytic
distribution of S100B in human brain. BMC Neurosci 2007, 2:8–2.
51. Koller E, Schneider B, Bennett K, et al: Clozapine-associated diabetes.
Am J Med 2001, 111:716–23.
52. American Psychiatric Association: Diagnostic and Statistical Manual of Mental
Disorders. DSM–IV–TR. 4th edition. Washington, DC: American Psychiatric
Press; 1994.
53. Woods SW: Chlorpromazine equivalent doses for the newer atypical
antipsychotics. J Clin Psychiatry 2003, 64:663–667.
54. Overall JE, Gorham DR: The brief psychiatric rating scale. Psychol Rep 1962,
10:799–812.
55. Andreasen N: Negative symptoms in schizophrenia. Arch Gen Psychiatry
1982, 39:784–788.
56. Wilson PWF, D’Agostino RB, Levy D, et al: Prediction of coronary heart
disease using risk factor categories. Circulation 1998, 97:1837–1847.
57. Osby U, Correia N, Brandt L, et al: Mortality and causes of death in schizophrenia
in Stockholm County, Sweden. Schizophr Res 2000, 45(1–2):21–28.
58. Spelman LK, Walsh PI, Sharifi N, et al: Impaired glucose tolerance in first-
episode drug-naïve patients with schizophrenia. Diabet Med 2007, 24:481–485.
59. Choong E, Bondolfi G, Etter M, et al: Psychotropic drug-induced weight
gain and other metabolic complications in a Swiss psychiatric
population. J Psychiatr Res 2012, 46:540–8.
60. Hughes JR, Hatsukami DK, Mitchell JE, et al: Prevalence of smoking among
psychiatric outpatients. Am J Psychiatry 1986, 143:8.
61. van Engelen BG, Lamers KJ, Gabreels FJ, et al: Age related changes of
neuron-specific enolase, S-100 protein, and myelin basic protein
concentrations in cerebrospinal fluid. Clin Chem 1992, 38:813–816.
62. Nygaard O, Langbakk B, Romnera B: Age- and sex-related changes of S-100
protein concentrations in cerebrospinal fluid and serum in patients with no
previous history of neurological disorder. Clin Chem 1997, 43:541–543.
63. Wiesmann M, Missler U, Gottmann D, et al: Plasma S-100b protein
concentration in healthy adults is age- and sex-independent. Clin Chem
1998, 44:1056–1058.
64. Gazzolo D, Michetti F, Bruschettini M, et al: Pediatric concentrations of
S100B protein in blood: Age- and Sex-related changes. Clin Chem 2003,
49:967–970.
65. Dev KK, Mullershausen F, Mattes H, et al: Brain S1P receptors: implication for
fingolimod in the treatment of multiple sclerosis. Pharmacol Ther 2008, 117:77–93.
66. Gonçalves CA, Leite MC, Guerra MC: Adipocytes as an important source of
serum S100B and possible roles of this protein in adipose tissue.
Cardiovasc Psychiatry Neurol 2010, 2010:790431.
67. Netto CB, Conte S, Leite MC, et al: Serum S100B protein is increased in
fasting rats. Arch Med Res 2006, 37:683–6.
68. Holtkamp K, Bühren K, Ponath G, et al: Serum levels of S100B are
decreased in chronic starvation and normalize with weight gain. J Neural
Transm 2008, 115:937–40.
69. Barreira TV, Staiano AE, Harrington DM, et al: Anthropometric correlates of
total body fat, abdominal adiposity, and cardiovascular disease risk factors
in a biracial sample of Men and women. Mayo Clin Proc 2012, 87(5):452–460.
70. Meltzer HY, Chai BL, Thompson PA, et al: Effect of scopolamine on the
efflux of dopamine and its metabolites after clozapine, haloperidol or
thioridazine. J. Pharm. Exp. Ther 1994, 268:1452–1461.
71. Konopaske GT, Dorph-Petersen KA, Sweet RA, et al: Effect of chronic
antipsychotic exposure on astrocyte and oligodendrocyte numbers in
macaque monkeys. Biol Psychiatry 2008, 63:759–65.
72. Stanwood GD: Protein-protein interactions and dopamine D2 receptor
signaling: a calcium connection. Mol Pharmacol 2008, 74:317–9.
73. Hearst SM, Lopez ME, Shao Q, et al: Dopamine D2 receptor signaling
modulates mutant ataxin-1 S776 phosphorylation and aggregation.
J Neurochem 2010, 114(3):706–16.
74. Dempsey BR, Shaw GS: Identification of calcium-independent and
calcium-enhanced binding between S100B and the dopamine D2
receptor. Biochemistry 2011, 50(42):9056–65.
75. Liu J, Wang H, Zhang L, et al: S100B transgenic mice develop features of
Parkinson’s disease. Arch Med Res 2011, 42(1):1–7.
doi:10.1186/1471-244X-13-146
Cite this article as: O’Connell et al.: Levels of S100B are raised in female
patients with schizophrenia. BMC Psychiatry 2013 13:146.
